Unicycive Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Unicycive Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Unicycive Therapeutics Inc
Rating: 0.97966675
Author: Trendlyne DVM scores

about

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed ...

4.42 0.00 (0.00%)

59.82% Fall from 52W High

324.9K

XNAS Volume

XNAS 30 Jul, 2025 4:07 PM (EDT)

Not Eligible

Expensive Valuation

4.2 / 100

Technically Neutral

35.0 / 100

1Yr Price target upside is 41%

6 analysts

Unicycive Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Unicycive Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed ...

59.82% Fall from 52W High

SWOT Analysis

Unicycive Therapeutics Inc Live Price Chart